Enyo aims for Phase II HBV, NASH trials with €40M round

Enyo Pharma S.A. (Lyon, France) raised €40 million ($46.8 million) in a series B round led by OrbiMed Advisors. New investors Andera Partners (formerly Edmond de Rothschild Investment Partners) and Bpifrance Large Venture also participated, as did Sofinnova Partners, Morningside Venture Investments, InnoBio and Inserm Transfert Initiative.

By year end, the company hopes to begin two Phase II trials of lead candidate EYP001 to treat chronic HBV infection and non-alcoholic steatohepatitis. The therapy, a small molecule agonist of farnesoid X receptor (FXR; NR1H4), is in a Phase Ib trial to treat HBV...